Investors & Media

Corporate Profile

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases and disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB).

We released topline results from three pivotal Phase 3 clinical trials for the treatment of H. pylori infection, the treatment of erosive GERD, and the treatment of symptomatic non-erosive GERD.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

January 8, 2023

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p...

January 3, 2023

FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced that the U.S....

November 8, 2022

Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023   Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total financing potentially...

Latest Events